Editas Medicine price to sales ratio EDIT

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 7.8×
8-year median: 29.3×
Against its 8-year history: 29th; percentile: 0 is its lowest day, 100 its highest
8-year range: 1.6× to 114×
Peer median: 3.6×

Editas Medicine's price to sales ratio is 7.8× as of Oct 23, 2026.

That is below its 8-year median of 29.3×, lower than on 71% of days in the last 8 years.

Over that time it ranged from 1.6× in Dec 2024 to 114× in Dec 2019.

The median for 4 biotech stocks of a similar size is 3.6×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	7.8×	3.7×	10.6×
2025	4.6×	1.6×	9.1×
2024	1.6×	1.6×	30.2×
2023	33.6×	21.6×	38.4×
2022	23.8×	23.7×	70.2×
2021	74.1×	24.6×	106×
2020	47.7×	19.3×	110×
2019	109×	33.6×	114×

Against its peers

Companies in Biotechnology nearest Editas Medicine's size, closest first, today.

Company	Price to sales ratio
EDITEditas Medicine	7.8×
PLXProtalix BioTherapeutics	2.5×
MGTXMeiraGTx	2.2×
VCELVericel	7.1×
ADMAAdma Biologics	4.7×
Peer median	3.6×

Where Editas Medicine ranks

#36of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Editas Medicine

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.